がんは多数のバイオマーカーの存在によって特徴付けられ、その多くは精密医療の標的として使用されています。さまざまな有望ながんタンパク質の中でも、クローディン-18(CLDN18)は、かなりの治療効果が期待できる魅力的な選択肢となっています。特に、CLDN18の変種であるCLDN18.2の出現が注目されています。CLDN18.2の発現パターンは明瞭で、主に胃粘膜に存在します。この変異体は、特定の悪性腫瘍との関連によって注目を集めています。CLDN18の治療可能性に関する研究が進む中、製薬分野への影響は大きく、一部のがんの治療方法に革命をもたらす可能性があります。
目次
Table of Content
1. Claudin 18.2 Therapy - New Epoch For Cancer Treatment
2. Introduction To Claudin 18.2 Therapy
2.1 Understanding Claudin 18.2 Proteins
2.2 Chronicle and Development of Claudin 18.2 Therapy
3. Need For Claudin 18.2 Targeted Therapy
4. Research Advancement Targeting Claudin 18.2 For Cancer Immunotherapy
4.1 Monoclonal Antibody Therapy
4.2 Bispecific Antibody
4.3 CAR T Cell Therapy
4.4 Antibody Drug Conjugate
5. Claudin 18.2 Therapy In Gastric and Pancreatic Cancer: Clinical Trends and Innovations
5.1 Gastric Cancer
5.2 Pancreatic Cancer
6. Global Claudin 18.2 Current Market Trend and Developments
6.1 Current Market Development Outlook
6.2 Future Market Outlook
7. Claudin 18.2 Therapy Trend Analysis By Region
7.1 US
7.2 China
7.3 Europe
7.4 UK
7.5 Japan
7.6 Australia
7.7 South Korea
8. Global Claudin 18.2 Drugs Clinical Trials Overview
8.1 By Company
8.2 By Country
8.3 By Therapy Class
8.4 By Indication
8.5 By Patient Segment
8.6 By Phase
9. Global Claudin 18.2 Drugs Clinical Trials By Company, Indication and Phase
9.1 Research
9.2 Preclinical
9.3 Phase-I
9.4 Phase-I/II
9.5 Phase-II
9.6 Preregistration
10. Technical and Clinical Platforms For Developing Advanced Claudin 18.2 Therapy
11. Global Claudin 18.2 Therapy Market Dynamics
11.1 Market Drivers
11.2 Market Challenges
12. Competitive Landscape
12.1 Abpro Therapeutics
12.2 Antengene Corporation
12.3 Arovella Therapeutics
12.4 Astellas Pharma
12.5 AstraZeneca
12.6 Beijing Mabworks Biotech
12.7 BioNTech
12.8 Biotheus
12.9 CARsgen
12.10 Dragonboat Biopharmaceutical
12.11 Gracell Biotechnology
12.12 Harbour BioMed
12.13 Innovent Biologics
12.14 Integral Molecular
12.15 Klus Pharma
12.16 L and L Biopharma
12.17 LaNova Medicines Limited
12.18 Leap Therapeutics
12.19 Luye Pharma Group
12.20 Nanjing Bioheng Biotech
12.21 Nanjing KAEDI Biotech
12.22 NBE-Therapeutics
12.23 OriCell Therapeutics
12.24 Qilu Pharmaceutical
12.25 Shanghai Junshi Biosciences
12.26 Sparx Therapeutics
12.27 Tillead Therapeutics
12.28 TORL Biotherapeutics
12.29 Transcenta Holding
12.30 Zai Biopharmaceutical
List of Figures
Figure 2-1: Function of Claudin 18.2 Protein
Figure 2-2: Functional Classification of the Claudin Family Proteins
Figure 2-3: Dichotomous Role of Claudin 18.2 Protein in Cancer
Figure 2-4: Claudin 18 Isoforms
Figure 3-1: Global - Gastric Cancer Incidences and Deaths (Million), 2020
Figure 4-1: Therapeutic Approach for Claudin 18.2 protein
Figure 4-2: mAb - Mode of Action
Figure 4-3: Claudin 18.2 - Novel Monoclonal Antibodies in Clinical Research
Figure 4-4: Advantage of Bispecific Antibodies
Figure 4-5: PT886 - Phanes Therapeutics Development Vista
Figure 4-6: Q-1802 Phase I/II Study - Initiation and Completion Year
Figure 4-7: QLS31905 Phase I/II Study - Initiation and Completion Year
Figure 4-8: ASP2138 - Astellas Pharma
Figure 4-9: CARsgen Pharmaceuticals Collaboration - Fudan and Peking University for CT041 and CT048
Figure 4-10: Immunofoco - Pipeline for Claudin 18.2 Therapy
Figure 4-11: NCT06084286 Phase I Study - Initiation and Completion Year
Figure 4-12: SKB315 - Clinical Trial and Collaboration Overview
Figure 4-13: RC118 Phase I/I Study - Initiation and Completion Year
Figure 4-14: Claudin 18.2 -ADCs Candidates
Figure 5-1: Upregulation of Claudin 18.2 in Gastric Cancer
Figure 5-2: HEC-016 Phase I Study - Initiation and Completion Year
Figure 5-3: Structure and Mode of Action for TJ-CD4B
Figure 5-4: Osemitamab Phase I/II Study - Initiation and Completion Year
Figure 5-5: LY011 Phase I/II Study - Initiation and Completion Year
Figure 5-6: SOT102 Phase I Study - Initiation and Completion Year
Figure 5-7: KD-496 Phase I Study - Initiation and Completion Year
Figure 5-8: SPX-101 Phase I Study - Initiation and Completion Year
Figure 5-9: Zolbetuximab Phase II Study - Initiation and Completion Year
Figure 6-1: Companies involved in Clinical Trial for Claudin 18.2 Therapy
Figure 6-2: Global - Claudin 18.2 Target Therapy Market (US Million), 2024 - 2028
Figure 6-3: Aspects Determining the Future of Claudin 18.2 Therapy
Figure 7-1: TAC101-CLAUDIN 18.2 Phase I Study - Initiation and Completion Year
Figure 7-2: Triumvira Immunologics - Pipeline for Claudin 18.2 Therapies
Figure 7-3: TORL-2-307 Phase I Study - Initiation and Completion Year
Figure 7-4: Aspects Influencing the Claudin 18.2 Therapy in US
Figure 7-5: China - Major Candidates in Clinical Trial
Figure 7-6: LM302 Phase II Study - Initiation and Completion Year
Figure 7-7: Strategic Collaboration Between LaNova and Turning Point
Figure 7-8: TQB2103 Phase I Study - Initiation and Completion Year
Figure 7-9: CARsgen Therapeutics Pipeline for Claudin 18.2
Figure 7-10: CT041 Phase II Study - Initiation and Completion Year
Figure 7-11: NCT06084286 Phase I Study - Initiation and Completion Year
Figure 7-12: SOT102 Phase I/II Study - Initiation and Completion Year
Figure 7-13: AZD0901 Phase II Study - Initiation and Completion Year
Figure 7-14: AZD0901 Phase II Study - Initiation and Completion Year
Figure 7-15: CMG901 - Partnership Between AstraZeneca and KYM Bioscience
Figure 7-16: Zolbetuximab - Reasons for Approval of Biologics License Application and Priority Designations
Figure 7-17: SPOTLIGHT Phase III Study - Initiation and Completion Year
Figure 7-18: GLOW Phase III Study - Initiation and Completion Year
Figure 7-19: ASP2138 Phase I Study - Initiation and Completion Year
Figure 7-20: Collaboration of SparX Group and Arovella Therapeutics for Claudin 18.2 iNKT cell therapy
Figure 7-21: ATG-022 Phase I Study - Initiation and Completion Year
Figure 8-1: Global - Claudin 18.2 Drugs Clinical Trials by Company (Numbers), 2023 till 2028
Figure 8-2: Global - Claudin 18.2 Drugs Clinical Trials by Country (Numbers), 2023 till 2028
Figure 8-3: Global - Claudin 18.2 Drugs Clinical Trials by Therapy Class (Numbers), 2023 till 2028
Figure 8-4: Global - Claudin 18.2 Drugs Clinical Trials by Indication (Numbers), 2023 till 2028
Figure 8-5: Global - Claudin 18.2 Drugs Clinical Trials by Patient Segment (Numbers), 2023 till 2028
Figure 8-6: Global - Claudin 18.2 Drugs Clinical Trials by Phase (Numbers), 2023 till 2028
Figure 10-1: CARsgen Pharmaceuticals - CycloCAR platform
Figure 10-2: LaNova - LX-ADCandtrade; Platform
Figure 10-3: Phanes Therapeutics - PACbody
Figure 10-4: Phanes Therapeutics - SPECpair
Figure 11 1: Market Drivers for Claudin 18.2 Therapy
Figure 11 2: Market Challenges for Claudin 18.2 Therapy
List of Tables
Table 2-1: Subfamilies of Claudin involved in Different Types of Cancer Formation
Table 4-1: Monoclonal Antibody Approaches Targeting Claudin 18.2 Protein
Table 4-2: Bispecific Antibody Approaches Targeting Claudin 18.2 Protein
Table 4-3: CAR-T Therapy Approaches Targeting Claudin 18.2 Protein
Table 4-4: Antibody Drug Conjugate Approaches Targeting Claudin 18.2 Protein
Table 5-1: Gastric Cancer - Ongoing Clinical Trials For Claudin 18.2 Therapy
Table 7-2: US - Ongoing Clinical Trial for Claudin 18.2 Therapy
Table 7-1: China - Ongoing Clinical Trials for Claudin 18.2 Therapy
Table 7-3: EU - Ongoing Clinical Trial for Claudin 18.2 Therapy
Table 7-5: UK- Ongoing Clinical Trial for Claudin 18.2 Therapy
Table 7-4: Japan - Ongoing Clinical Trial for Claudin 18.2
Table 7-6: Australia - Ongoing Clinical Trial for Claudin 18.2
Table 7-7: South Korea - Ongoing Clinical Trial for Claudin 18.2
